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Aims Prolonged P2Y-receptor signalling can cause vasoconstriction leading to hypertension, vascular smooth muscle
hypertrophy, and hyperplasia. G protein-coupled receptor signalling is negatively regulated by G protein-coupled
receptor kinases (GRKs) and arrestin proteins, preventing prolonged or inappropriate signalling. This study investi-
gates whether GRKs and arrestins regulate uridine 5′-triphosphate (UTP)-stimulated contractile signalling in adult
Wistar rat mesenteric arterial smooth muscle cells (MSMCs).
Methods
and results
Mesenteric arteries contracted in response to UTP challenge: When an EC50 UTP concentration (30 mM, 5 min) was
added 5 min before (R1) and after (R2) the addition of a maximal UTP concentration (Rmax: 100 mM, 5 min), R2
responses were decreased relative to R1, indicating desensitization. UTP-induced P2Y-receptor desensitization of
phospholipase C signalling was studied in isolated MSMCs transfected with an inositol 1,4,5-trisphosphate biosensor
and/or loaded with Ca
2+-sensitive dyes. A similar protocol (R1/R2 ¼ 10 mM; Rmax ¼ 100 mM, applied for 30 s)
revealed markedly reduced R2 when compared with R1 responses. MSMCs were transfected with dominant-negative
GRKs or siRNAs targeting speciﬁc GRK/arrestins to probe their respective roles in P2Y-receptor desensitization.
GRK2 inhibition, but not GRK3, GRK5, or GRK6, attenuated P2Y-receptor desensitization. siRNA-mediated knock-
down of arrestin2 attenuated UTP-stimulated P2Y-receptor desensitization, whereas arrestin3 depletion did not.
Speciﬁc siRNA knockdown of the P2Y2-receptor almost completely abolished UTP-stimulated IP3/Ca
2+ signalling,
strongly suggesting that our study is speciﬁcally characterizing this purinoceptor subtype.
Conclusion These new data highlight roles of GRK2 and arrestin2 as important regulators of UTP-stimulated P2Y2-receptor
responsiveness in resistance arteries, emphasizing their potential importance in regulating vasoconstrictor signalling
pathways implicated in vascular disease.
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1. Introduction
Extracellular nucleotides play important roles in cardiovascular physi-
ology, and in vascular tissues prolonged nucleotide signalling has been
implicated in the pathophysiology of restenosis, diabetic microvascular
disease, and hypertension.
1 Purine/pyrimidine nucleotide release can
have different effects on vascular tone depending on the site of
release and cell type(s) with which the nucleotide interacts.
1 Nucleo-
tides released from endothelial cells after shear stress and/or hypoxia
can cause smooth muscle relaxation;
1,2 contrastingly, nucleotide
release from sympathetic neuronal inputs act directly on vascular
smooth muscle causing contraction.
1,3,4
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tor, including the ionotropic P2X and metabotropic P2Y receptor
families.
5 Vascular smooth muscle cell contractile responses are
mediated through the P2X1 subtype and several P2Y subtypes (i.e.
P2Y2,4,6). P2X1-receptors cause a rapid inﬂux of Ca
2+ to initiate
smooth muscle contraction. The G protein-coupled receptors
(GPCRs) P2Y2, P2Y4, and P2Y6 couple with Gaq/11 proteins to acti-
vate phospholipase C (PLC), generating inositol 1,4,5-trisphosphate
(IP3) and diacylglycerol. This initiates the mobilization of intracellular
Ca
2+ stores, activation of protein kinase C, and induces contrac-
tion.
1,5 Both P2X- and P2Y-mediated pathways are known to contrib-
ute signiﬁcantly to the control of vascular tone.
3,6,7
Considering the potentially important roles that P2Y-receptors
may play in the aetiology of vascular disease, very little is currently
known regarding the regulation of their signalling in vascular smooth
muscle. P2Y-receptors, like most GPCRs, are known to undergo
desensitization,
8,9 a process which can prevent prolonged/
inappropriate receptor-mediated signalling.
10 Desensitization of
agonist-occupied GPCRs is usually initiated by the recruitment of G
protein-coupled receptor kinases (GRKs), which phosphorylate key
serine/threonine residues within the third intracellular (i3) loop and/
or C-terminal tail of the GPCR.
10 GRK-mediated phosphorylation
promotes the binding of non-visual arrestins (arrestin2 and/or
arrestin3), which sterically inhibit GPCR-G protein interactions,
and promote receptor internalization.
10,11 Of the seven GRK isoen-
zymes (GRK1–7) and four arrestin isoforms (arrestin1–4) expressed
in mammals, GRK2, GRK3, GRK5, and GRK6, and arrestin2
(b-arrestin-1) and arrestin3 (b-arrestin-2) are commonly reported
to be ubiquitously expressed.
10 Here, we have characterized the
desensitization and resensitization of P2Y-receptor responses in
mesenteric arterial smooth muscle cells (MSMCs), a widely documen-
ted model of systemic resistance arteries.
12 Furthermore, we have
combined confocal imaging with biochemical and molecular biological
manipulation of individual GRK and arrestin subtypes to identify their
roles in the regulation of endogenous P2Y-receptor-stimulated PLC
signalling and contraction of MSMCs.
2. Methods
2.1 Isolation and culture of MSMCs
Adult male Wistar rats were killed by cervical dislocation, a method
approved under the United Kingdom Animals (Scientiﬁc Procedures)
Act 1986. The investigation also conforms to the Guide for Care and
Use of Laboratory Animals US (NIH Publication No. 85-23, revised
1996). Smooth muscle cells were isolated from small branches of mesen-
teric artery by enzymatic dissociation as previously described.
12 Smooth
muscle cells were separated by gentle trituration in 231 medium
(Cascade Biologics, Nottingham, UK), supplemented with smooth
muscle growth supplement, 100 IU/mL penicillin, 100 mg/mL streptomy-
cin, and 2.5 mg/mL amphotericin B. Cells plated onto coverslips were
maintained at 378C and 5% CO2 in humidiﬁed conditions.
2.2 Myography
Contractile force recordings were made from 2 to 4 mm ring segments of
third-order mesenteric arteries mounted in a Mulvany-Halpern wire myo-
graph (JP Trading, Denmark). The bath solution contained (mM): NaCl
134, KCl 6, MgCl2 1, CaCl2 1.8, glucose 4, mannitol 6, HEPES 10, pH
7.4. NaCl was reduced to 81 mM and replaced with 60 mM K
+ for the
high K
+ solution. All bathing solutions contained L-NAME (20 mM) to
prevent endogenous nitric oxide production. Solutions and drugs were
added directly to the organ bath, maintained at 378C.
2.3 Relative contributions of P2Y receptors
to MSMC Ca
21 signalling
MSMCs were plated into 96-well multiplates. Monolayers ( 90% con-
ﬂuency) were loaded with the Ca
2+-sensitive dye Fluo4-AM (3 mM) at
room temperature for 60 min. Selective P2Y2/4/6-receptor agonists
(Tocris, Bristol, UK) were added and changes in intracellular Ca
2+
levels ([Ca
2+]i) were determined as the relative change in ﬂuorescence
using a NovoStar imaging system (BMG Labtech, Aylesbury, UK).
2.4 Single cell confocal imaging
UTP-stimulated PLC activity was determined in MSMCs transfected (24–
48 h after isolation) with the pleckstrin-homology domain of phospho-
lipase Cd1 tagged with enhanced green ﬂuorescent protein (eGFP-PH,
0.5 mg an extensively characterized IP3 biosensor
13) using confocal
imaging exactly as previously described
14 (see Supplementary material
online). Changes in cytosolic eGFP-PH ﬂuorescence are displayed as the
ﬂuorescence emission (F)/initial basal ﬂuorescence (F0)( F/F0). Additional
Ca
2+ experiments in the absence of eGFP-PH were conducted using
Fluo-4-AM (3 mM, 60 min) and imaged as for eGFP.
2.5 Manipulating cellular GRK and
arrestin levels
To assess the role that GRKs play in the regulation of P2Y-receptor
signalling, MSMCs were co-transfected with eGFP-PH (0.5 mg), and
the following dominant-negative, catalytically inactive GRK mutants:
D110A,K220RGRK2,
D110A,K220RGRK3,
K215RGRK5,
K215RGRK6 (0.5 mg),
14
or negative control plasmid (pcDNA3). Additionally, GRK2 expression
was depleted using anti-GRK2 small interfering (si)RNA (10 nM) [with
non-targeting siRNA as negative-control (NC)].
14 Our previous data
demonstrated that co-transfection rates are .90%,
14 therefore we have
assumed that eGFP-expressing cells are successfully co-transfected. To
examine the role that arrestins play in the regulation of P2Y-receptor sig-
nalling, MSMCs were transfected with anti-arrestin2 (5′-GCCACUGACU
CGGCUACAAtt-3′; 100 nM), anti-arrestin3 (5′-GCCUUCUGUGCCAA
AUCUAtt-3′; 100 nM), or NC siRNA (100 nM) (Applied Biosystems,
UK). Arrestin depletion was assessed 48 h after nucleofection (Lonza
AG, Cologne, Germany) by immunoblotting using an anti-arrestin2 anti-
body (A1CT). Arrestin expression was quantiﬁed using the GeneGnome
image analysis system (Syngene, Cambridge, UK). For signalling studies,
MSMCs were transfected using Lipofectamine2000 (Invitrogen, Paisley,
UK) according to manufacturer’s instructions and PLC activity assessed
as described above.
2.6 Manipulating cellular P2Y receptor levels
An siRNA approach was also applied to delineate the respective roles of
P2Y2- and P2Y4-receptors in UTP-mediated signalling. MSMCs were trans-
fected with differing concentrations of anti-P2Y2 (5′-GAACUGACACUG
UGAGGAAtt-3′), or anti-P2Y4 (5′-CGUCUACUUCAGUUCGGCAtt-3′)
siRNAs. To validate the siRNAs and to quantify P2Y2/P2Y4 knockdown,
rat aortic smooth muscle cells were nucleofected and after 48 h lysed,
mRNA isolated and transcribed into cDNA, prior to PCR ampliﬁcation
using a LightCycler instrument (Roche Applied Science, Burgess Hill,
UK). Data are presented as DCT values (calculated as CT (scrambled
siRNA-transfected cells)2CT (anti-P2Y siRNA-transfected cells)). A
more detailed method is provided in the accompanying Supplementary
Material.
2.7 Data and statistical analysis
Data presented are from cells obtained from at least three separate prep-
arations, expressed as means+SEM. Data were analysed using one-way
G.E. Morris et al. 194ANOVA as indicated, with appropriate post hoc testing (GraphPad Prism,
San Diego, CA, USA).
3. Results
3.1 Characterization of UTP-mediated
contractions in mesenteric arteries
Concentration-dependent contractions of third-order mesenteric
arteries (Figure 1A and B) were induced by UTP addition, with
maximal contraction seen at UTP concentrations ≥50 mM (EC50
28 mM). Repeated addition of maximal UTP (100 mM, 5 min) concen-
trations, interspersed by 5 min wash periods produced robust arterial
contractions with little evidence of tachyphylaxis (data not shown).
These ﬁndings are consistent with those previously obtained for H1
histamine receptor-mediated Ca
2+ responses,
15 where desensitiza-
tion is masked by the presence of signiﬁcant cell/tissue receptor
reserve with respect to the observed response. To uncover any
potential loss of UTP-induced contractile responsiveness, an
amended protocol was applied where arteries were challenged with
an approximate EC50 concentration of UTP (30 mM) for 5 min
before (R1) and after (R2) the addition of a maximal UTP
Figure 1 Characterization of UTP-stimulated contractions of third-order mesenteric arteries. (A) Representative trace showing K
+-induced con-
traction followed by washout and concentration-dependent UTP (0–100 mM)-stimulated contractions (B) Cumulative concentration-dependent UTP-
stimulated arterial contraction data shown as means+SEM for arterial preparations from at least four animals. (C–E) Desensitization protocol:
arteries were exposed to 30 mM UTP (R1, for 1 min) challenge, followed by 5 min washout, maximal UTP (Rmax ¼ 100 mM, 1 min) challenge, followed
by a variable period of 2–15 min washout before a further 30 mM UTP (R2, 1 min) exposure. Representative traces from single arteries with either a
5 min (C) or 15 min (D) Rmax-to-R2 washout period are shown. (E) Time-course of resensitization of the contractile response to UTP expressed as a
percent change in R2 relative to R1 (means+SEM for arterial preparations from at least four animals).
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5 min between R1 and Rmax, and for 2–15 min between Rmax and R2
agonist challenges. Reduced R2/R1 ratios are interpreted as an index
of receptor/tissue desensitization.
14,15 R2 contractile responses com-
pared with R1 were dramatically reduced (by  80%) following Rmax
exposure when the inter-Rmax/R2 delay was 2 min (Figure 1E); extend-
ing the inter-Rmax/R2 wash period revealed a time-dependent resensi-
tization of UTP-induced contractions with the R1/R2 ratio returning to
 1 after 12–15 min (Figure 1C–E).
3.2 Characterization of UTP-mediated
Ca
21 signalling in isolated MSMC
Vascular smooth muscle cells are known to express several
UTP-responsive (types 2/4/6) P2Y-receptors,
1 although it has not
been conclusively determined which receptors contribute to UTP-
stimulated Ca
2+ signals, particularly in mesenteric smooth muscle.
Therefore, various P2Y2-, P2Y4- and P2Y6-selective agonists were
utilized to characterize the P2Y-receptor subtypes present in our
preparation. The P2Y2-selective agonist 2-thio-UTP was more
potent [pEC50 (M) ¼ 6.56], but less efﬁcacious than UTP [pEC50
(M) ¼ 5.23] in causing concentration-dependent [Ca
2+]i increases
in MSMCs. The P2Y4-selective agonists, inosine 5′-triphosphate,
and UTPgS produced almost identical responses, again showing a
slightly reduced efﬁcacy relative to UTP (Supplementary material
online, Figure S1B). The P2Y6-selective agonist PSB0474 failed to
cause any Ca
2+ signals, while the P2Y6-selective antagonist
MRS2578 (10 mM) had no signiﬁcant effect on the UTP-mediated
[Ca
2+]i response (Supplementary material online, Figure S1C).
Since our data suggested that MSMCs express a mixed P2Y2/
P2Y4-receptor population, we applied an siRNA approach speciﬁ-
cally to deplete the expression of these P2Y-receptor subtypes indi-
vidually. The effectiveness of siRNA constructs to suppress P2Y2-
and P2Y4-receptor mRNAs was determined using real-time
reverse transcription-polymerase chain reactions (RT-PCR) (see
Section 2.6) in rat aortic smooth muscle cells 48 h after nucleofec-
tion with siRNA constructs targeting P2Y2- or P2Y4-receptor
mRNAs or a NC (non-targeting) siRNA. Data show that nucleofec-
tion with NC siRNA had no effect on P2Y2 or P2Y4 signals (data not
shown), while in the presence of anti-P2Y2 siRNA, mean P2Y2 cycle
threshold values were suppressed (DCT ¼ 22.0, relative to NC
siRNA-transfected samples), with no effect on the P2Y4 signal
(Figure 2A). Conversely, anti-P2Y4 siRNA suppressed mean cycle
threshold values for P2Y4 (DCT ¼ 23.4), but was without effect
on P2Y2 signals. Neither P2Y-targeting siRNA altered b-actin
mRNA levels signiﬁcantly (data not shown). Collectively, these
data suggest that ≥75% and ≥90% P2Y mRNA transcripts are
selectively depleted following transfection of rat vascular smooth
muscle with anti-P2Y2 or anti-P2Y4 siRNAs, respectively. The contri-
butions P2Y2- and P2Y4-receptors play in UTP-mediated PLC signal-
ling were determined in MSMCs co-transfected with eGFP-PH and
NC, anti-P2Y2 or anti-P2Y4 siRNAs. NC siRNA nucleofection had
no signiﬁcant effect on the magnitude and proﬁle of UTP-stimulated
responses in MSMCs (data not shown). UTP-induced eGFP-PH
translocation was virtually ablated in MSMCs treated with
anti-P2Y2 siRNA, whereas anti-P2Y4 siRNA treatment was without
effect (Figure 2C–E). Furthermore, responses to endothelin-1 were
also unaltered following P2Y2-depletion (Figure 2C). Collectively,
these data strongly suggest that in cultured MSMCs, UTP-mediated
signalling via PLC is mediated primarily and perhaps exclusively by
P2Y2-receptors.
3.3 Desensitization and resensitization
of UTP-signalling in isolated MSMC
Time-courses of desensitization/resensitization of receptor–PLC sig-
nalling in response to UTP were assessed using similar protocols as
those described above for myography experiments, however
shorter agonist applications at lower concentrations (R1/R2 10 mM
UTP, 30 s; Rmax 100 mM UTP, 30 s) were sufﬁcient to induce
signiﬁcant desensitization (Figure 3). Comparison of UTP-induced
changes in IP3 (eGFP-PH translocation) and [Ca
2+]i (Fluo4), before
(R1) and after (R2) the desensitizing UTP (Rmax) challenge resulted
in a 64% decrease for [Ca
2+]i and 84% decrease for IP3 in R2 vs. R1
measured 2 and 3 min after Rmax challenge, respectively (Figure 3A,
C, and E). Prolonging the inter-Rmax/R2 washout period revealed a
time-dependent resensitization of UTP-stimulated IP3 and [Ca
2+]i
responses (Figure 3B, D, and E), with essentially complete recovery
of UTP-stimulated IP3 and [Ca
2+]i responses after 15 and 10 min,
respectively (Figure 3E).
3.4 GRK isoenzymic dependency of
P2Y-receptor desensitization in MSMCs
To determine whether endogenous GRKs regulate UTP signalling in
MSMCs, individual GRK isoenzymes were inhibited using catalytically
inactive, dominant-negative mutant GRKs. MSMCs were co-transfected
with eGFP-PH (0.5 mg) together with pcDNA3 (control),
D110A,K220R
GRK2,
D110A,K220RGRK3,
K215RGRK5, or
K215RGRK6 (0.5 mg).
14 When
subjected to the previously described desensitization protocol (with
5 minwashesbetweenR1/Rmax/R2agonistadditions),MSMCstransfected
with pcDNA3,
D110A,K220RGRK3,
K215RGRK5, or
K215RGRK6 displayed
similar reductions in R2 responses ( 70%) compared with R1,c o m p a r -
able to responses observed in non-transfected cells (Figure 4).
However, the presence of
D110A,K220RGRK2 signiﬁcantly attenuated
reductions in the R2 response when compared with R1 (Figure 4B and
F), suggesting that endogenous GRK2 activity plays a signiﬁcant role in
regulating UTP-stimulated P2Y-receptor-mediated PLC/Ca
2+ signalling.
To corroborate these ﬁndings, we applied a previously validated
siRNA that speciﬁcally depletes endogenous GRK2 (by ≥75%)
without altering the expression of non-targeted GRKs.
14 MSMCs
were co-transfected with eGFP-PH (0.5 mg) and either 10 nM
anti-GRK2 or NC siRNAs and 48 h later subjected to the standard
R1/Rmax/R2 desensitization protocol (Figure 5A and B). In agreement
with our data from
D110A,K220RGRK2 co-transfections, siRNA-induced
depletion of GRK2 attenuated the decrease in R2 (relative to R1)
caused by Rmax UTP-addition (Figure 5B and C). This was most striking
for the eGFP-PH/IP3 response (R2/R1 (%), negative control siRNA,
32+8; anti-GRK2 siRNA, 71+7; P , 0.05; data are means+
SEM). Taken together, these ﬁndings strongly suggest that GRK2 is
a key mediator of UTP-induced P2Y2 receptor desensitization.
3.5 Arrestin dependency of P2Y2-receptor
desensitization in MSMCs
To examine the potential role that arrestin proteins play in regulat-
ing P2Y2-receptor signalling, we utilized an siRNA approach to selec-
tively deplete endogenous arrestin2/3 expression. MSMCs were
transfected with anti-arrestin2, anti-arrestin3, or NC siRNAs
(100 nM) 48 h prior to cell lysis and immunoblotting. Substantial
G.E. Morris et al. 196arrestin depletion (.70% for arrestin2 and arrestin3) was observed
at this time-point, and both arrestin2- and arrestin3-targeted
siRNAs appeared to be highly selective for their respective targets
(Figure 6A and B). To determine the effects of arrestin depletion
on the desensitization of UTP-stimulated PLC signalling, MSMCs
were co-transfected with eGFP-PH (0.5 mg) and anti-arrestin2 or
anti-arrestin3, before being subjected to the standard R1/Rmax/R2
desensitization protocol. In the absence or presence of NC siRNA
reductions in R2 relative to R1 responses of ≥80% for eGFP-PH
and ≥70% for [Ca
2+]i signals were observed (Figure 6C and E).
Selective depletion of arrestin2 markedly reversed UTP-induced
decreases in R2 relative to R1 IP3/Ca
2+ responses (Figure 6E). Con-
trastingly, while arrestin3 depletion had a small effect on R2/R1
ratios (Figure 6E), this did not achieve statistical signiﬁcance,
suggesting that attenuation of the UTP signal is primarily effected
by the arrestin2 isoform.
Previously we showed that GRK2 regulates endothelin (ETA)
receptor desensitization,
14 suggesting that ETARs are also likely sub-
strates for arrestin recruitment in MSMCs. Consequently, the poten-
tial involvement of arrestin proteins in the regulation of ETA receptor
signalling was assessed in MSMCs co-transfected with eGFP-PH and
either anti-arrestin2 or anti-arrestin3 siRNAs. Here, ETA receptor
desensitization was assessed by exposing cells to a short desensitizing
pulse of endothelin-1 (50 nM, 30 s, termed R1) followed by a 10 min
wash period and second endothelin-1 challenge (50 nM, 30 s, termed
R2). The extent of receptor desensitization, assessed at the level of IP3
Figure 2 Dissecting the P2Y2/P2Y4-receptor dependency of UTP signalling. (A) Real-time PCR data showing changes in cycle threshold (DCT) values
for P2Y2 or P2Y4 transcripts, relative to negative-control (NC) and untransfected cells, following transfection with 100 nM of anti-P2Y2 or anti-P2Y4
receptor siRNAs. Data shown are means+SEM for n ¼ 6 experiments (in triplicate) undertaken in cell preparations from six separate animals. Repre-
sentative traces (B–D) and cumulative data (E) showing affects of NC (B), anti-P2Y2 (C), or anti-P2Y4 (D) siRNAs on UTP-stimulated (10 or 100 mM)
IP3 signals. Data expressed as means+SEM for n ¼ 8–10 cells from cell preparations produced from four or more separate animals. Statistical sig-
niﬁcance is indicated as asterisk **P , 0.01 vs. NC siRNA (one-way ANOVA, Dunnett’s post hoc test).
GRK2 and arrestin2 regulate UTP-mediated arterial contraction 197Figure 3 Time-course of UTP-induced P2Y2-receptor desensitization. MSMCs were transfected with eGFP-PH (0.5 mg), or loaded with Fluo4 and
subjected to the following desensitization protocol: cells were challenged with UTP (R1,1 0mM, 30 s) 5 min before a desensitizing UTP concentration
(Rmax ¼ 100 mM for 30 s), and again after a variable washout period (2, 3, 5, 10, or 15 min) (R2,1 0mM, 30 s). Representative traces and images from
single cells either expressing eGFP-PH (A and B) or loaded with Fluo4 (C and D) with either a 3 (A and C), 10 (B), or 15 min (D) wash period are
shown. P2Y2 receptor desensitization was determined as the relative (%) change in R2 response compared with R1 for both eGFP-PH and Fluo4
signals. (E) Cumulative data are presented as means+SEM for ﬁve to nine cells (eGFP-PH), or 21–45 cells (Fluo4) at each time-point. MSMCs
used were generated from preparations from three or more different animals.
G.E. Morris et al. 198Figure 4 GRK2 inhibition decreases P2Y2-receptor desensitization induced by UTP. MSMCs were co-transfected with 0.5 mg eGFP-PH and either
pcDNA3 (control),
D110A,K220RGRK2,
D110A,K220RGRK3,
K215RGRK5, or
K215RGRK6 (0.5 mg). Cells were subjected to the standard R1/Rmax/R2 protocol
(see Section 2). Representative traces show IP3 changes in cells transfected with pcDNA3 (A),
D110A,K220RGRK2 (B),
D110A,K220RGRK3 (C),
K215RGRK5
(D), or
K215RGRK6 (E). P2Y receptor desensitization was determined as the relative (%) change in R2 response compared with R1.( F) Cumulative data
are presented as means+SEM from 13–19 cells from MSMC preparations from four or more different animals. Statistical signiﬁcance is indicated as
asterisk **P , 0.01 vs. vector-transfected MSMCs (one-way ANOVA; Dunnett’s post hoc test).
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2+, was similar in the absence or presence of NC, or anti-
arrestin2 siRNAs (Figure 6F and H), whereas, in anti-arrestin3 siRNA-
transfected MSMCs endothelin-1-induced receptor desensitization
was signiﬁcantly attenuated (Figure 6G and H). These data suggest
while both P2Y2- and ETA-receptors are desensitized via a
GRK2-dependent mechanism in MSMCs, it is likely that different
arrestins are recruited to the desensitized receptor, with P2Y2- and
ETA-receptors preferentially recruiting arrestin2 and arrestin3,
respectively.
4. Discussion
The relative importance of different P2 receptor subtypes present
in smooth muscle for contraction is complex and delineation of the
contributions of speciﬁc subtypes complicated by the lack of highly
selective agonists/antagonists. Available data suggest that G protein-
coupled P2Y2, P2Y4, and P2Y6 receptors, and ionotropic P2X1 recep-
tors contribute to nucleotide-mediated contraction.
4,16 Furthermore,
evidence from aortic smooth muscle cells suggests that P2Y-receptor
mRNA abundance differs between contractile and synthetic pheno-
types, with decreases in P2Y4/P2Y6, and increases in P2Y2 mRNA
being observed in the synthetic phenotype.
17 Our pharmacological
and siRNA knockdown data indicate that UTP/PLC responses in
isolated MSMCs are primarily mediated by P2Y2 receptors, which
concurs with previous ﬁndings that UTP-mediated contractions in
mesenteric arteries (.180 mm) are sensitive to blockade by the
P2Y2-selective antagonist suramin.
16 Furthermore, our UTP-
stimulated arterial contractile (EC50 28 mM) and MSMC Ca
2+ (EC50
6 mM) responses are comparable to those reported in small
(.100 mm) mesenteric arteries.
16
Previous studies have described desensitization of P2Y2-receptor
responses in several cell backgrounds,
8,9,18,19 however, few studies
have addressed the regulation of native P2Y2-receptor responsiveness
and none to our knowledge have done so in mesenteric arteries. In
human promonocytic U937, astrocytoma 132N1 and epithelial
HT-29 cells P2Y2-receptor desensitization has been reported to
occur rapidly and is enhanced following phorbol ester addition,
however in all cases inclusion of PKC inhibitors failed to prevent
receptor desensitization.
9,18 Indeed, the observed attenuations of sig-
nalling may have been the result of PKC-mediated inhibition of PLC
activity.
20 Interestingly, protein phosphatase inhibitors can attenuate
P2Y2-receptor resensitization.
18 Collectively, these ﬁndings suggest
that P2Y2-receptor phosphorylation, by a kinase(s) other than PKC
is required for desensitization.
18 Our preliminary experiments
demonstrated that a protocol similar to that utilized to study H1
histamine-receptor desensitization allows quantitative assessment of
the desensitization of MSMC responses to UTP.
15 By employing a pro-
tocol where a sub-maximally effective ( EC50) concentration of
agonist is added to cells before (R1) and after (R2) a maximal, desen-
sitizing agonist exposure (Rmax), attenuations of responsiveness are
detected irrespective of P2Y2-receptor reserve. Moreover, we have
extended this approach and utilized a similar R1/Rmax/R2 protocol in
small, intact mesenteric vessels ( 150 mm diameter) to assess recep-
tor desensitization/resensitization at the level of the UTP-evoked con-
tractile response. Interestingly, our data indicate that UTP-stimulated
Figure 5 Depletion of endogenous GRK2 attenuates P2Y2-
receptor desensitization. MSMCs were nucleofected with 0.5 mg
eGFP-PH and either negative-control (NC) or anti-GRK2 (10 nM)
siRNAs. Cells were loaded with Fura-Red and subjected to the stan-
dard R1/Rmax/R2 desensitization protocol (see Section 2). Represen-
tative traces are shown for single cells transfected with NC siRNA
(A) or anti-GRK2 siRNA (B). P2Y receptor desensitization was
determined as the relative (%) change in R2 response compared
with R1. Cumulative data (C) show means+SEM from 8 to 15
cells from MSMCs prepared from more than four separate
animals. Statistical signiﬁcance is indicated as *P , 0.01 vs. NC
siRNA-treated MSMCs (one-way ANOVA; Dunnett’s post hoc test).
G.E. Morris et al. 200Figure 6 Depletion of endogenous arrestin2 attenuates P2Y2-receptor desensitization. MSMCs were nucleofected with NC, anti-arrestin2 or anti-
arrestin3 siRNAs (100 nM) (see Section 2). After 48 h, cells were lysed and 40 mg of protein loaded for SDS–PAGE separation and immunoblotting.
(A) Representative immunoblot showing arrestin2 depletion (upper panel), and the same blot is shown after longer exposure to highlight arrestin3
(lower panel, lower band) depletion, shown in: non-transfected cells (lane 1), or cells treated with 100 nM of anti-arrestin2 (lane 2), anti-arrestin3
(lane 3), or NC (lane 4) siRNAs. (B) Cumulative densitometric data show mean arrestin expression+SEM from four animal cell preparations,
**P,0.01 vs. NC siRNA (one-way ANOVA; Dunnett’s post hoc test). To assess the effects of arrestin depletion on UTP- or ET1-stimulated PLC
signalling, MSMCs were nucleofected with 0.5 mg eGFP-PH and with 100 nM of either NC, anti-arrestin2 or anti-arrestin3 siRNAs. Cells were
loaded with Fura-Red and subjected to the standard R1/Rmax/R2 (for UTP) or R1/R1 (for ET-1) desensitization protocols (see Section 2). Representative
traces from single cells transfected with control siRNA (C and F), anti-arrestin2 (D), or anti-arrestin3 (G). Traces (C) and (D) show UTP responses,
while (F) and (G) show ET-1 responses. Cumulative data are shown as means+SEM from 5 to 13 cells from preparations from three to four separate
animals for UTP- (E) and ET1-stimulated cells (H). Statistical signiﬁcance is indicated as *P , 0.05 or **P , 0.01 vs. NC siRNA-treated MSMCs
(one-way ANOVA; Dunnett’s post hoc test).
GRK2 and arrestin2 regulate UTP-mediated arterial contraction 201intact vessel contractions are relatively resistant to desensitization
when compared with PLC/Ca
2+ responses in primary MSMCs.
These differences might relate to the differing capacities of intact
mesenteric smooth muscle and cultured MSMC preparations to
metabolize UTP, and/or ex vivo changes in receptor populations
and/or post-receptor components. Nevertheless, using comparable
protocols, it is possible to assess the time-course of receptor desen-
sitization/resensitization with respect to both UTP-stimulated con-
tractile and signalling responses in tissue/cell preparations.
Since GRK proteins are known to regulate the signalling of other
PLC-coupled GPCRs expressed in MSMCs,
14,21,22 we initially utilized
dominant-negative (kinase-dead) GRK mutants to disrupt P2Y2-
receptor/GRK isoenzyme-speciﬁc interactions in an attempt to
attenuate or prevent the reduction in receptor responsiveness
observed on re-addition of UTP subsequent to a desensitizing pulse
of this agonist. The
D110A,K220RGRK2 construct, which has been
mutated to prevent both kinase activity and Gaq/11-binding,
20 mark-
edly attenuated P2Y2-receptor desensitization. Conversely, over-
expression of
D110A,K220RGRK3,
K215RGRK5, or
K215RGRK6 mutants
affected neither the extent of desensitization, nor the time-course
of recovery of P2Y2-receptor responsiveness to UTP. To complement
our ﬁndings (and address any potential criticisms associated with the
recombinant over-expression of GRK mutants), we also depleted
(.75%) endogenous GRK2 expression in MSMCs using isoenzyme-
speciﬁc siRNAs, producing near-identical data to those obtained
using the
D110A,K220RGRK2 construct.
Together these ﬁndings indicate that GRK2 is a key endogenous
GRK isoenzyme initiating P2Y2-receptor desensitization in MSMCs,
with either GRK2 knockdown or disruption of the normal
GRK2-receptor interaction causing an  60% attenuation of agonist-
stimulated P2Y2-receptor desensitization; a ﬁgure only  15% less
than that achievable after full receptor resensitization. It is possible
that GRK2 is the only kinase involved in initiating P2Y2-receptor
desensitization and that the observed partial effects arise because
the experimental ablations of GRK2 activity are incompletely effective.
On the other hand, while a predominant GRK isoenzyme can often be
identiﬁed as being responsible for initiating receptor desensitization it
is rare for this to be the only protein kinase involved.
23,24 Therefore,
other (minor) mechanisms may yet be shown to be involved in regu-
lating P2Y2-receptor responsiveness in MSMCs.
GRK2 has previously been reported to be the key GRK isoenzyme
regulating angiotensin II type 1 (AT1),
25 a1D-adrenergic,
22 and ETA
14
receptor-mediated contractile responses. The ﬁnding that GRK2 is
also key to the regulation of P2Y2-receptor signalling further empha-
sizes the importance of this GRK isoenzyme in Gaq/11/PLC-coupled
receptor regulation in arterial smooth muscle.
GRK-mediated phosphorylation often leads to arrestin recruitment
to the receptor, promoting internalization, receptor recycling, and/or
downregulation.
10,11 When expressed in HEK293 cells, P2Y2-
receptors recruit both exogenous arrestin2 and arrestin3,
26
however, while suggestive that P2Y2 receptors can interact with
arrestin proteins, these studies are not necessarily predictive of
how, or if, these receptors are regulated in native tissues. Here, we
utilized an RNAi strategy to suppress individual arrestin isoform
expression to delineate for the ﬁrst time their role in P2Y2 receptor
regulation in resistance artery smooth muscle. Our data indicate a
high degree of isoform-selective arrestin interaction with P2Y2, with
siRNA-mediated depletion of arrestin2 almost completely attenuating
UTP-stimulated P2Y2-receptor desensitization. Conversely,
knockdown of arrestin3 was without effect on P2Y2 signalling. We
also assessed whether another important vasoconstrictor GPCR
also differentially recruits arrestin2/3 isoforms, and showed that
ETA-receptor responses are attenuated by arrestin3, but not arrestin2
knockdown. Moreover, we recently showed that GRK2 is also a criti-
cal kinase involved in ETA-receptor desensitization.
14 Consequently,
our ﬁndings clearly demonstrate that phosphorylation by a common
GRK isoenzyme can lead to contrasting arrestin isoform recruitment.
A likely explanation that deserves future investigation is that the
pattern of GRK2-mediated P2Y2- and ETA-receptor phosphorylation
differs sufﬁciently to promote differential recruitment of arrestins.
Finally, the potential importance of arrestin recruitment in vascular
disease has been highlighted by two recent studies. Data from arrestin
knockout mice reveal a role for arrestins in the regulation of vascular
smooth muscle migration and proliferation during atherosclerosis and
neointimal hyperplasia,
27 while arrestin3 regulates angiotensin
II-stimulated, ERK-mediated aortic smooth muscle proliferation.
28
Since our new ﬁndings highlight a selective arrestin regulation of
ETA- and P2Y2-receptors, it is likely that differential recruitment of
arrestins to phosphorylated GPCRs has the potential to determine
physiological and pathophysiological signalling outcomes activated by
UTP and ET-1.
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